Loading...
Loading...
In a report published Friday, Jefferies analyst Brandon Couillard assumed coverage on
CepheidCPHD, downgraded the rating from Buy to Hold, but reiterated the $38.00 price target.
In the report, Jefferies noted, “CPHD is well-positioned to realize significant margin expansion over the coming years as it leverages investments in its R&D pipeline, launches new high-margined tests and captures greater manufacturing efficiencies. However, present valuations (+20% vs. historical avg) already appear to reflect bullish growth expectations, in our view. Assuming coverage at Hold / $38 target.”
Cepheid closed on Thursday at $36.62.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in